All articles by Staff Writer
Staff Writer
QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of QCI Secondary Analysis, a cloud-based software-as-a-services (SaaS) solution enabling high-throughput secondary analysis for use with any clinical next-generation sequencing (NGS) data.
Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech
Bruker Corporation (Nasdaq: BRKR) is pleased to announce the closing of its acquisition of ELITechGroup (“ELITech”) for €870 million in cash, excluding the carved out ELITech clinical chemistry business. ELITech is a differentiated, fast growing and profitable provider of systems and assays for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology, with FY 2023 revenue of approximately EUR 150 million, and more than 80% consumables revenue.
Australian Government Grants TB Alliance an Award to Help Bolster Clinical Research and Improve Access to New Treatments for Drug-Resistant TB
AUD 17 Million Grant over 5 Years Will Fund Next-Generation TB Cures
New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World
Hub will focus on supporting global use of new treatments that effectively treated drug-resistant TB in 98% of Filipino participants
XRP Healthcare Partner with NHS collaborator Isansys Lifecare to Revolutionize Healthcare Services in Uganda
XRP Healthcare is thrilled to announce a strategic partnership with Isansys Lifecare, a leading innovator in the digital healthcare technology sector, to enhance healthcare infrastructure and services across Uganda. This collaboration is set to transform patient care through the integration of advanced patient monitoring systems into the pharmacies, medical centres and hospitals they are set to acquire during this year throughout the country.
TNO launches Peregrion to boost market impact of its technology that accelerates medicine development
TNO spin-off Peregrion brings science to the marketplace
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from three real-world retrospective studies being presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI).
Hybribio Calls for Raising International HPV Awareness
March 4th 2024 marks the 7th International HPV Awareness Day, a global campaign proposed by the International Papillomavirus Society (IPVS) since 2018. This year, the theme is One Less Worry. On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.
SEKISUI Diagnostics Receives Emergency Use Authorization for the OSOM® Flu SARS-CoV-2 Combo Test
SEKISUI Diagnostics, a global medical diagnostics manufacturer, has received EUA clearance for the OSOM Flu SARS-CoV-2 Combo Test for use in professional and home testing settings.
Diasorin receives FDA 510(k) clearance for its Liaison Plex® System, the new multiplexing platform of the group, together with the Liaison Plex® Respiratory Panel
Diasorin (FTSE MIB: DIA) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company’s new LIAISON PLEX® platform as well as its first panel of tests, the LIAISON PLEX® Respiratory Flex Assay.